Latest period
$16.63M
YoY change
-27.2%
5Y CAGR
-9.9%
Peak year (2013)
$26.87M
Latest annual
$7.49M
Total Liabilities history chart for Relmada Therapeutics (RLMD) from 2012 to 2025
Latest: $7.49M
Total Liabilities growth chart for Relmada Therapeutics (RLMD) from 2012 to 2025
Latest: -27.2%
Total Liabilities history table for Relmada Therapeutics (RLMD) from 2012 to 2025
| 2025 | $7.49M | -27.2% | −$2.80M | ||
| 2024 | $10.30M | -15.6% | −$1.90M | ||
| 2023 | $12.19M | -2.2% | −$274.08K | ||
| 2022 | $12.47M | -17.2% | −$2.59M | ||
| 2021 | $15.06M | +19.5% | +$2.46M | ||
| 2020 | $12.60M | +764.5% | +$11.15M | ||
| 2019 | $1.46M | -44.1% | −$1.15M | ||
| 2018 | $2.61M | -69.6% | −$5.95M | ||
| 2017 | $8.56M | +521.9% | +$7.18M | ||
| 2016 | $1.38M | -57.0% | −$1.83M | ||
| 2015 | $3.20M | -79.5% | −$12.38M | ||
| 2014 | $15.58M | -42.0% | −$11.29M | ||
| 2013 | $26.87M | +384025.4% | +$26.87M | ||
| 2012 | $7.00K | — | — |
- 2025$7.49M-27.2%
- 2024$10.30M-15.6%
- 2023$12.19M-2.2%
- 2022$12.47M-17.2%
- 2021$15.06M+19.5%
- 2020$12.60M+764.5%
- 2019$1.46M-44.1%
- 2018$2.61M-69.6%
- 2017$8.56M+521.9%
- 2016$1.38M-57.0%
- 2015$3.20M-79.5%
- 2014$15.58M-42.0%
- 2013$26.87M+384025.4%
- 2012$7.00K—
Total Liabilities values are taken from Relmada Therapeutics's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Liabilities at Relmada Therapeutics (RLMD)
According to Relmada Therapeutics's latest reported financial statements, the company's latest reported total liabilities is $16.63M. Total liabilities sum everything the company owes at the end of each reporting period — accounts payable, accrued expenses, debt, lease obligations, and other claims — as filed on the balance sheet. Compare with total assets and total equity for solvency context.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Relmada Therapeutics (RLMD) most recent annual total liabilities stands at $7.49M (2025) – declined 27.2% year-over-year.
Relmada Therapeutics total liabilities has contracted on net over the period, with a -9.9% compound annual growth rate over 2020–2025 (5 years).
2013 marks the peak total liabilities at $26.87M, with the historical low of $7.00K recorded in 2012.
Relmada Therapeutics Total Liabilities by Year
Relmada Therapeutics Total Liabilities 2025: $7.49M
Relmada Therapeutics total liabilities in 2025 was $7.49M, declined 27.2% below 2024.
Relmada Therapeutics Total Liabilities 2024: $10.30M
2024's total liabilities for Relmada Therapeutics came in at $10.30M, declined 15.6% below 2023.
Relmada Therapeutics Total Liabilities 2023: $12.19M
Relmada Therapeutics posted total liabilities of $12.19M in 2023, edged down 2.2% below 2022.
Relmada Therapeutics Total Liabilities 2022: $12.47M
In 2022, Relmada Therapeutics reported total liabilities of $12.47M, declined 17.2% below 2021.
Relmada Therapeutics Total Liabilities 2021: $15.06M
Relmada Therapeutics total liabilities in 2021 was $15.06M.
See more financial history for Relmada Therapeutics (RLMD).
Sector peers by Total Liabilities
Healthcare peers of Relmada Therapeutics (RLMD), ranked by their latest total liabilities
| $207.88B | |
| $137.19B | |
| $117.67B | |
| $85.94B | |
| $84.20B | |
| $81.93B | |
| $65.36B | |
| $54.86B |
- $207.88B
- $137.19B
- $117.67B
- $85.94B
- $84.20B
- $81.93B
- $65.36B
- $54.86B
Frequently asked questions
Relmada Therapeutics (RLMD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation